How Can Hyper-automated AI Bridge Life Sciences Companies to Complete Digital Transformation?


Hyper-automated AI has moved beyond futuristic speculation and firmly established itself in the present, revolutionizing industries worldwide and delivering superior efficiencies and insights through a comprehensive suite of machine learning, robotics, natural language query, and other technologies.
Life sciences companies, immersed in the daily data deluge, stand to benefit greatly as well. This technology can significantly enhance existing digital capabilities, transforming complex healthcare data into actionable intelligence in a fraction of the time it would traditionally take.
However, while all this certainly sounds very promising (and be that as it may), it is impossible to ignore the necessary changes that organizations will have to undergo before reaching this milestone.
Join industry experts Nuray Yurt (Merck), Ravi Shankar (Novartis), Nadia Tantsyura (Boehringer Ingelheim), Nitin Raizada (Indegene), and Vikas Mahajan (Indegene) as they unpack top use cases and winning execution strategies for Hyper-automated AI in life sciences.
Key questions that will be addressed include:

  • Where and how hyper-automated AI can be implemented in life sciences
  • Why this technology should be a strategic necessity versus a tactical choice
  • How to prepare for such disruptive technology
  • Why it’s not a robotic overthrow of humans
  • How to deal with interoperability challenges


  • Vikas Mahajan, Senior Director of Data and Analytics, Indegene


  • Ravi Shankar, Executive Director of Data and Analytics Enablement and Strategic Data Products, Novartis
  • Nuray Yurt, Business Engagement and Activation Lead for Digital Data and Analytics, Merck
  • Nadia Tantsyura, Global Capability Owner of Data Domain and Analytics, Boehringer Ingelheim
  • Nitin Raizada, Vice President of Enterprise Commercial Solutions, Indegene

Back to: